– Major Medical Journal Retracts Numerous Scientific Papers After Fake Peer-Review Scandal (ZeroHedge, June 8, 2015):
A major publisher of scholarly medical and science articles has retracted 43 papers because of “fabricated” peer reviews amid signs of a broader fake peer review racket affecting many more publications. As The Washington Post reports, BioMed Central – a well-known publication of peer-reviewed journals – shows a partial list of the retracted articles suggests most of them were written by scholars at universities in China. The Committee on Publication Ethics stated, it “has become aware of systematic, inappropriate attempts to manipulate the peer review processes of several journals… that need to be retracted.”
Peer review is the vetting process designed to guarantee the integrity of scholarly articles by having experts read them and approve or disapprove them for publication. With researchers increasingly desperate for recognition, citations and professional advancement, the whole peer-review system has come under scrutiny in recent years for a host of flaws and irregularities, ranging from lackadaisical reviewing to cronyism to outright fraud.
And as The Washington Post reports, BioMed Central, based in the United Kingdom, which puts out 277 peer-reviewed journals of scholarly medical and science articles has retracted 43 papers because of “fabricated” peer reviews amid signs of a broader fake peer review racket affecting many more publications…
A partial list of the retracted articles suggests most of them were written by scholars at universities in China. But Jigisha Patel, associate editorial director for research integrity at BioMed Central, said it’s not “a China problem. We get a lot of robust research of China. We see this as a broader problem of how scientists are judged.”
Meanwhile, the Committee on Publication Ethics, a multidisciplinary group that includes more than 9,000 journal editors, issued a statement suggesting a much broader potential problem.
The committee, it said, “has become aware of systematic, inappropriate attempts to manipulate the peer review processes of several journals across different publishers.” Those journals are now reviewing manuscripts to determine how many may need to be retracted, it said.
Ivan Oransky and Adam Marcus, the co-editors of Retraction Watch, a blog that tracks research integrity and first reported the BioMed Central retractions, have counted a total of 170 retractions in the past few years across several journals because of fake peer reviews.
“The problem of fake peer reviewers is affecting the whole of academic journal publishing and we are among the ranks of publishers hit by this type of fraud,” Patel of BioMed’s ethics group wrote in November.
“The spectrum of ‘fakery’ has ranged from authors suggesting their friends who agree in advance to provide a positive review, to elaborate peer review circles where a group of authors agree to peer review each others’ manuscripts, to impersonating real people, and to generating completely fictitious characters. From what we have discovered amongst our journals, it appears to have reached a higher level of sophistication. The pattern we have found, where there is no apparent connection between the authors but similarities between the suggested reviewers, suggests that a third party could be behind this sophisticated fraud.”
In a blog post yesterday, Elizabeth Moylan, BioMed Central’s senior editor for research integrity, said an investigation begun last year revealed a scheme to “deceive” journal editors by suggesting “fabricated” reviewers for submitted articles. She wrote that some of the “manipulations” appeared to have been conducted by agencies that offer language-editing and submission assistance to non-English speaking authors.
Perhaps most astonishing was the fact that…
Ultimately, when they tracked down some of the scientists in whose names reviews were written, they found that they hadn’t written them at all. Someone else had, using the scientists’ names.
But that Chinese Micro-cap Biotech stock is definitely still worth buying… even after rising 3000% YTD.